Clinical Trial

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

Study acronym: BroADen
Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-17; most recent amendment 2026-01-22.
Status change: Active, Not Recruiting → Completed 2026-01-22
Status change: Recruiting → Active, Not Recruiting 2025-09-30
Status change: Not Yet Recruiting → Recruiting 2025-04-28
Trial Details
NCT Number NCT06945458
Lead Sponsor Kymera Therapeutics, Inc.
Conditions Atopic Dermatitis
Enrollment 22 participants
Start Date 2025-04-17
Primary Completion 2025-11-10 (estimated)
Study Completion 2025-11-10 (estimated)
Updated on ClinicalTrials.gov 2026-01-26